Drug intelligence / Profile preview

GVX 3322

Development stage: Preclinical
Lead developer: Genvax
Modality: Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics

Overview

GVX 3322 is a DNA-based therapeutic vaccine designed for the treatment of prostate cancer. Developed by Genvax, a subsidiary of Medical Marketing International Group (MMI), the vaccine utilizes a DNA sequence verified for commercial assembly. It was developed in collaboration with the University of Southampton and Cancer Research Technology. The vaccine is intended to stimulate an immune response against prostate cancer cells. As of 2008, it was in preclinical development with plans for Phase II clinical trials following immunogenicity studies. It underwent preclinical equivalence studies comparing it to an academic vaccine previously used in clinical trials.

Beyond the preview

Go deeper on GVX 3322.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GVX 3322.

Explore the full profile